BridgeBio, Consecutively Participates in Global Pharmaceutical and Bio Events

Participation in China Healthcare Summit and Bio Europe
Introduction of Major R&D Projects

Bridge Biotherapeutics announced on the 2nd that it will participate in the '10th China Healthcare Summit' and '2023 BIO Europe.'

Bridge Biotherapeutics logo. [Photo by Bridge Biotherapeutics]

The company plans to promote its development pipeline worldwide and seek global partnerships.

The China Healthcare Summit, held from the 2nd to the 3rd of this month (local time) in Shanghai, China, is an annual conference co-hosted by the U.S. pharmaceutical and biotech magazine BioCentury and the Chinese life sciences nonprofit organization BayHelix. Since 2014, it has brought together key figures from the pharmaceutical and biotech industries in China and around the world to explore the globalization of the Chinese pharmaceutical industry and new collaboration opportunities.

Bridge Biotherapeutics plans to present its major research and development achievements focused on cancer and fibrotic diseases to global pharmaceutical and biotech industry stakeholders and institutional investors during the corporate presentation session at the China Healthcare Summit.

Jung-kyu Lee, CEO of Bridge Biotherapeutics, will personally serve as a speaker to introduce the development status and future strategies of the company’s core clinical projects: the autotaxin inhibitor 'BBT-877' being developed as a treatment for idiopathic pulmonary fibrosis (IPF), and the 4th-generation epidermal growth factor receptor (EGFR) inhibitor 'BBT-207' targeting non-small cell lung cancer (NSCLC). At the same time, the company will unveil for the first time on the international stage the new solid tumor drug candidate 'BBT-778,' a TEA domain (TEAD) inhibitor series discovered by its U.S. subsidiary Boston Discovery Center (BDC).

From the 6th to the 8th, Bridge Biotherapeutics will participate in BIO Europe, the largest pharmaceutical and biotech partnering event in the European region held in Munich, Germany, where it will hold business development partnering meetings with numerous multinational pharmaceutical and biotech companies. The company also plans to continue efforts to explore new projects in its strategic disease areas of idiopathic pulmonary fibrosis and cancer therapeutics at BIO Europe.

Bridge Biotherapeutics recently received a recommendation from an Independent Data Monitoring Committee (IDMC) to continue the Phase 2 clinical trial of BBT-877 and is currently administering the drug to more than 40 patients. Additionally, with the initiation of dosing for NSCLC patients with BBT-207, the company expects business development discussions related to its core projects to gain momentum.

Jung-kyu Lee, CEO of Bridge Biotherapeutics, stated, "We hope this event will be an opportunity to actively showcase the results of our research and development projects focused on lung cancer and pulmonary fibrosis, the two main disease areas we concentrate on, confirm the needs of global partners, and strengthen our network. We will make company-wide efforts to quickly present meaningful outcomes through participation in major global business development events this month."